Treatment with Adempas (riociguat) is generally safe and effective for people with pulmonary arterial hypertension (PAH) and coexisting cardiometabolic conditions, or those that affect the heart and metabolism, according to a pooled analysis of clinical trials. “Efficacy and risk assessment results suggest that [Adempas] can be beneficial for…

Adempas (riociguat), an approved therapy for adults with pulmonary arterial hypertension (PAH), was well-tolerated in children and adolescents with PAH, with no new safety signals, according to data from PATENT-CHILD — the first pediatric trial of the therapy. The medication, used off-label for pediatric PAH patients with doses tailored…

Answer: resilience. Randolph Reynolds is geared up and ready to fly an F-105 in 1978. (Courtesy of Randolph Reynolds) Randolph Reynolds, 81, had an amazing career as a jet fighter and instructor pilot in the United States Air Force, flying magnificent aircraft like the F-105 Thunderchief and F-4D Phantom…

Treatment with Adempas (riociguat) improved blood flow measurements in people with pulmonary hypertension and heart failure with preserved ejection fraction (HFpEF) in a clinical trial. Researchers say that further study is needed to determine the effect of Adempas on clinical outcomes like exercise capacity. The study, “…

Living with pulmonary hypertension (PH) is a constant challenge. If I’m not educating myself, I’m educating my family and friends, and at times, even my medical team. Yes, the members of my medical team are experts in medicine, but I am the expert of my own body. Recently, I…

Intermediate-risk pulmonary arterial hypertension (PAH) patients may see their symptoms improve after switching from phosphodiesterase-5 inhibitors (PDE-5i) to Adempas (riociguat), results from the Phase 4 REPLACE clinical trial show. The transition to Adempas also appears to be a safer option than with PDE-5i maintenance therapy. The study, “Switching…

Long-term treatment with Bayer’s Adempas (riociguat) was safe and well-tolerated in people with pulmonary arterial hypertension (PAH), according to data from the real-world EXPERT study. These findings from clinical practice were consistent with those reported in previous clinical trials, supporting the therapy’s favorable safety profile. Data from EXPERT…

People with intermediate-risk pulmonary arterial hypertension (PAH) who failed to respond adequately to phosphodiesterase-5 inhibitors (PDE5i) show significant benefits when transitioned to Adempas (riociguat) treatment, a Phase 4 trial has found. A total of 41% of patients who made that transition experienced significant clinical improvements, compared with…

Over the last year, Pulmonary Hypertension News has brought you the latest news about groundbreaking discoveries, treatment developments, clinical trials, and other events related to pulmonary hypertension (PH). As we look ahead to 2020, here are our top 10 most-read stories of 2019, with a summary of their significance for…

Riociguat increases the risk of death and serious adverse events in people with pulmonary hypertension (PH) associated with idiopathic interstitial pneumonia (IIP), and should not be prescribed to those patients, final results of a Phase 2 study show. The study, “Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension…

The vasodilator Adempas (riociguat) increases the ability of endothelial progenitor cells to halt vascular remodeling and enhance formation of new blood vessels in chronic thromboembolic pulmonary hypertension (CTEPH), according to a new in vitro (in the lab) study. This may be particularly helpful for CTEPH patients…

A new meta-analysis assessing balloon pulmonary angioplasty (BPA) and Adempas (riociguat) for treating inoperable chronic thromboembolic pulmonary hypertension (CTEPH) found both treatment strategies to be well-tolerated, and able to improve exercise tolerance and the function of the circulatory system. The study with that finding, “Balloon…